VC-backed Concert Pharmaceuticals files for IPO – Fortune

Fortune reported that Concert Pharmaceuticals has filed for a $74.75 million IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol “CNCE.” UBS and Wells Fargo are the lead underwriters. Based in Lexington, Mass., Concert Pharmaceuticals produces drugs that treat spasticity and kidney disease. Its backers nclude Three Arch Partners, TVM Capital, GlaxoSmithKline, Brookside Capital, Skyline Ventures, Fidelity Investments, Greylock Partners and Flagship Ventures.

Related Posts

Leave a Reply

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups